DPI 221
Alternative Names: BIO302; DPI-221; MCP-202Latest Information Update: 16 Jun 2023
At a glance
- Originator Enhance Biotech
- Developer DMK Pharmaceuticals
- Class Benzamides; Fluorinated hydrocarbons; Piperazines; Small molecules; Urologics
- Mechanism of Action Opioid delta receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Benign prostatic hyperplasia; Urinary incontinence
Most Recent Events
- 16 Jun 2023 Chemical structure information added
- 27 Feb 2023 Phase I development is ongoing in USA (DMK Pharmaceuticals pipeline, February 2023)
- 27 Feb 2023 Phase-I clinical trials in Benign prostatic hyperplasia in USA (unspecified route) (DMK Pharmaceuticals pipeline, February 2023)